Amphastar (AMPH) announced FDA approval for their generic teriparatide injection pen. It is bioequivalent to Eli Lilly's Forteo. They plan to launch in the US late 2025 to compete in a $585 million market. The company is manufacturing the product entirely in-house at their US facility. This is an important development since the stock is down nearly 28% year-to-date and they are carrying high debt. Management has been buying back shares but execution on this new launch is critical to offset recent earnings pressure.